Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
lunes, noviembre 09
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Apyx Medical Corp
APYX
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$2.87
-0.06
-2.05%
Últ. Act.: Nov 6, 4:16 PM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Ganancias:
Los beneficios de Q3 2026 se publicaron el jue nov 5th, antes de la apertura del mercado
Conferencia telefónica:
La conferencia telefónica más reciente comenzó a las 4:30 p. m., hace 4 días
Haz clic para ver el webcast
Apyx Medical Financials
Apyx Medical (APYX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Apyx Medical Affirms FY2026 Sales Guidance of $59.000M-$60.000M vs $59.410M Est
Apyx Medical (NASDAQ:APYX) affirms FY2026 sales outlook from $59.000 million-$60.000 million to $59.000 million-$60.000 million vs $59.410 million estimate.
Benzinga Newsdesk
PRO
Apyx Medical Q3 EPS $(0.04) Beats $(0.09) Estimate, Sales $14.030M Beat $13.290M Estimate
Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.09) by 55.56 percent. This is a 20 percent increase over losses of $(0.05) per share from the
Benzinga Newsdesk
PRO
Apyx Medical Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $13.884M Beat $13.175M Estimate
Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 22.22 percent increase over losses of $(0.09) per share from the
Benzinga Newsdesk
PRO
Apyx Medical Affirms FY2026 Sales Guidance of $59.000M-$60.000M vs $59.554M Est
Apyx Medical (NASDAQ:APYX) affirms FY2026 sales outlook from $59.000 million-$60.000 million to $59.000 million-$60.000 million vs $59.554 million estimate.
Benzinga Newsdesk
PRO
Apyx Medical Raises FY2026 Sales Guidance from $57.500M-$58.500M to $59.000M-$60.000M vs $57.988M Est
Apyx Medical (NASDAQ:APYX) raises FY2026 sales outlook from $57.500 million-$58.500 million to $59.000 million-$60.000 million vs $57.988 million estimate.
Benzinga Newsdesk
PRO
Apyx Medical Q1 EPS $(0.05) Beats $(0.10) Estimate, Sales $12.490M Beat $10.868M Estimate
Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.10) by 50 percent. This is a 50 percent increase over losses of $(0.10) per share from the same
Benzinga Newsdesk
